Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 4/20 | 0.39 |
| ▸ | CASP1 | P29466 | 6/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.32 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14401098 | 0.76 | CTSB (0.40) | CTSBCASP1HRH1BACE1 | |
| Asparagine SCHEMBL7855644 | 0.72 | SLC1A3 (0.34) | — | |
| SCHEMBL13125899 | 0.67 | CTSB (0.47) | CTSBCASP1HRH1BACE1 | |
| SCHEMBL14401170 | 0.66 | BACE1 (0.35) | CTSBCASP1HRH1BACE1 | |
| SCHEMBL22882707 | 0.63 | SMN1; SMN2 (0.50) | — | |
| SCHEMBL22882705 | 0.63 | SMN1; SMN2 (0.50) | — | |
| SCHEMBL13125721 | 0.62 | HRH1 (0.38) | CTSBHRH1BACE1 | |
| SCHEMBL2906420 | 0.61 | OPRD1 (0.48) | BACE1 | |
| SCHEMBL14442118 | 0.61 | CTSB (0.50) | CTSBHRH1BACE1 | |
| SCHEMBL13209298 | 0.60 | MMP9 (0.45) | CASP1HRH1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239270-A2 | Low molecular weight peptide derivatives as inhibitors of the Laminin/Nidogen interaction | Sanofi-Aventis Deutschland GmbH (DE) | 2010-10-13 | — | — | EP | disclosed |
| EP-1845106-B1 | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-11 | — | — | EP | disclosed |
| EP-1845106-A1 | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | Sanofi-Aventis Deutschland GmbH (DE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1157040-B1 | LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-6365572-B1 | FOR THERAPY OF DISEASES RELATED TO INCREASED OR UNWANTED SYNTHESIS OF BASEMENT MEMBRANES SUCH AS DIABETES MELLITUS; ATHEROSCLEROSIS; CANCER; DIABETIC RETINOPATHIA; FIBROPLASIA RETROLENTALIS; OR PSORIASIS, RHEUMATOIC ARTHRITIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-1157040-A1 | LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION | Aventis Pharma Deutschland GmbH (DE) | 2001-11-28 | — | — | EP | disclosed |
| EP-1070727-A1 | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | Aventis Pharma Deutschland GmbH (DE) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000052051-A1 | LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-09-08 | — | — | WO | disclosed |